SLE (SYSTEMIC LUPUS)
Clinical trials for SLE (SYSTEMIC LUPUS) explained in plain language.
Never miss a new study
Get alerted when new SLE (SYSTEMIC LUPUS) trials appear
Sign up with your email to follow new studies for SLE (SYSTEMIC LUPUS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New lupus skin drug VENT-03 enters Mid-Stage trial
Disease control Recruiting nowThis study tests an experimental drug called VENT-03 in 24 adults with active cutaneous lupus (lupus that affects the skin), with or without systemic lupus. For the first 4 weeks, some participants get VENT-03 and some get a placebo; then everyone gets VENT-03 for 8 more weeks. T…
Matched conditions: SLE (SYSTEMIC LUPUS)
Phase: PHASE2 • Sponsor: Ventus Therapeutics U.S., Inc. • Aim: Disease control
Last updated Jun 16, 2026 22:21 UTC
-
Immune reset: CAR-T therapy targets lupus and other autoimmune conditions
Disease control Recruiting nowThis early-stage study is testing a new treatment using a patient's own immune cells, modified to target and attack faulty immune cells that cause autoimmune diseases like lupus, scleroderma, and Sjogren's syndrome. The goal is to see if this approach is safe and can control dise…
Matched conditions: SLE (SYSTEMIC LUPUS)
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
Gene-Edited immune cells take on lupus and scleroderma in first human test
Disease control Recruiting nowThis early-stage study tests a one-time treatment made from donor immune cells that are edited with CRISPR to target and calm the overactive immune system. It is for 80 adults with lupus, scleroderma, or myositis that have not responded to standard therapies. The main goal is to …
Matched conditions: SLE (SYSTEMIC LUPUS)
Phase: PHASE1 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New lupus drug CLN-978 enters early human testing
Disease control Recruiting nowThis early-stage study tests a new drug called CLN-978 in 24 people with moderate to severe lupus. The main goal is to see if the drug is safe and tolerable. Researchers will also measure how the drug moves through the body and how it affects immune cells. This is a first step to…
Matched conditions: SLE (SYSTEMIC LUPUS)
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC